Sonic HealthcareASX:SHL +0.15%82 EBITDA Margin % is 16.81% as of Dec. 2025, which is 8% below its 10-year median of 18.23. GuruFocus rates ASX:SHL with a GF Score™ of 82/100 and a GF Value™ of A$32.93 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Sonic Healthcare ranks better than 68.63% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sonic Healthcare's EBITDA for the
six
months ended in Dec. 2025 was A$915 Mil. Sonic Healthcare's Revenue for the
six
months ended in Dec. 2025 was A$5,445 Mil. Therefore, Sonic Healthcare's EBITDA margin for the quarter that ended in Dec. 2025 was 16.81%.
Sonic Healthcare (ASX:SHL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sonic Healthcare EBITDA Margin % Related Terms
Sonic Healthcare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sonic Healthcare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:SHL vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Sonic Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonic Healthcare EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sonic Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sonic Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonic Healthcare (ASX:SHL) has a EBITDA Margin % of 16.81% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sonic Healthcare and its competitors. This is near median its historical median of 18.23. Over the past decade, Sonic Healthcare's EBITDA Margin % has ranged from 16.94 to 30.39. According to the industry distribution chart, Sonic Healthcare ranks #64 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 31.4%.
Is Sonic Healthcare's EBITDA Margin % too high?
Sonic Healthcare's current EBITDA Margin % of 16.81% is near median its 10-year median of 18.23. Over the past 10 years, this metric has ranged from a low of 16.94 to a high of 30.39. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Sonic Healthcare's value of 16.81% is 223.3% above this industry median. Based on the distribution chart, Sonic Healthcare ranks #64 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Sonic Healthcare has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sonic Healthcare's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sonic Healthcare ranks #64 out of 204 companies for EBITDA Margin %. This puts Sonic Healthcare in the upper half of its industry. The industry median EBITDA Margin % is 5.20. Sonic Healthcare's value of 16.81% is 223.3% above this benchmark. Historically, Sonic Healthcare's own EBITDA Margin % has ranged from 16.94 to 30.39 over the past decade. While the company's 10-year median is 18.23 vs. the industry median of 5.20, Sonic Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sonic Healthcare's current EBITDA Margin % of 16.81% is 223.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sonic Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonic Healthcare's current EBITDA Margin % is 16.81%, which is near median its own 10-year median of 18.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonic Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sonic Healthcare (ASX:SHL) is currently considered Significantly Undervalued. The stock's GF Value™ is A$32.93, compared to a current price of A$19.86 — trading 39.7% below its estimated fair value. The current EBITDA Margin % is 16.81%, which is near median its 10-year median of 18.23 and 223.3% above the Medical Diagnostics & Research industry median of 5.20. Sonic Healthcare's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sonic Healthcare (ASX:SHL), the current EBITDA Margin % is 16.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonic Healthcare (ASX:SHL) Overvalued in 2026?
Based on GuruFocus' analysis, Sonic Healthcare stock appears to be undervalued.
The current stock price of A$19.86 is trading 39.7% below its estimated GF Value™ of A$32.93.
GuruFocus considers Sonic Healthcare to be Significantly Undervalued.
Key valuation signals for ASX:SHL:
EBITDA Margin %: 16.81% (near median its 10-year median of 18.23)
GF Value™: A$32.93 vs. price of A$19.86 (39.7% below fair value)
Industry Position: 223.3% above the Medical Diagnostics & Research median (#64 of 204)
No single metric tells the full story. See the ASX:SHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand, and the third largest in the US. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 35% of group revenue in Australia and New Zealand, 25% in the US, and 40% in Europe.
82GF Score
Get the complete analysis for ASX:SHL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SHL has been successfully added to your 
